2023 North America Conference on Lung Cancer (NACLC) - Posters and Abstracts-PP01.116 Reina Haque NACLC23 Abstract

PP01.116 Reina Haque NACLC23 Abstract

Pdf Summary

This study examined the utilization and discontinuation of durvalumab, a treatment for stage III unresectable non-small cell lung cancer (uNSCLC), in U.S. patients following concurrent chemoradiation. Durvalumab was initially approved for every two weeks (Q2W) dosing, but in November 2020, the FDA approved a fixed-dosing of 1,500 mg every four weeks (Q4W) based on pharmacological data and other studies. The researchers aimed to describe the utilization and discontinuation of durvalumab Q4W dosing in a large healthcare system in California where Q4W dosing was adopted during the pandemic.<br /><br />The study included adult patients with stage III uNSCLC who had completed concurrent chemoradiation and initiated durvalumab between March 2019 and December 2021. The researchers examined the patients' healthcare records and followed them until durvalumab discontinuation, health plan disenrollment, death, or study end.<br /><br />Of the 102 eligible patients, 42 were switched from Q2W to Q4W dosing and 60 initiated Q4W dosing. The average age of the patients was 71 years, and a large percentage had multiple comorbidities. The median duration of treatment, including interruptions, was 10 months overall and 7.5 months for the Q4W group. Overall, 46.1% of patients completed the year-long treatment, while 53.9% discontinued durvalumab early. The most common reasons for discontinuation were disease progression and pneumonitis.<br /><br />The study found that the Q4W dosing of durvalumab was well-tolerated in this real-world cohort, with a treatment duration and completion rate comparable to previous studies using Q2W dosing. No confirmed cases of COVID-19 were identified during durvalumab treatment.<br /><br />In conclusion, durvalumab Q4W dosing was effective and well-tolerated in U.S. patients with unresectable stage III NSCLC following concurrent chemoradiation. Nearly half of the patients completed one year of treatment, and the most common reasons for discontinuation were disease progression and pneumonitis. These findings contribute to the real-world evidence of durvalumab utilization in this patient population.

Keywords

durvalumab

utilization

discontinuation

uNSCLC

Q4W dosing

concurrent chemoradiation

healthcare records

disease progression

pneumonitis

real-world evidence